

New polymorphic form of ondansetron, processes for preparing them, pharmaceutical compositions containing them and their use as antiemetics

5 **Field of the invention**

This invention relates to a new polymorph of ( $\pm$ )1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, known under the INN of ondansetron.


10

This invention also relates to a process for preparing said polymorph, to pharmaceutical composition containing it and to its use in the treatment and prophylaxis of nausea and vomiting.

15

**Background of the invention**

The compound ( $\pm$ )1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is known under the INN of ondansetron and has the following  
20 structure:



Ondansetron is a selective antagonist of the 5-HT<sub>3</sub> receptor, which is marketed as an antiemetic.

25

Patent GB 2153821 describes ondansetron, its salts and solvates. In particular, the preparation of base ondansetron is described in several examples. Thus, in example 4, the preparation of base ondansetron is  
30 described by methylation with dimethyl sulphate in dimethylformamide; the product obtained melts with

decomposition at 223°C - 224°C. In example 7, base ondansetron is obtained by treatment of 3-[(dimethylamine)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride with 2-methylimidazol in 5 water, to yield ondansetron with a melting point of 221°C - 221.5°C, which following recrystallisation in methanol gives a melting point of 231°-232 °C. In example 8, the preparation of base ondansetron is described by treatment of 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-10 one with 2-methylimidazol in water followed by recrystallisation in methanol, to yield ondansetron with a melting point of 232°-234 °C with decomposition. In example 18, the preparation of base ondansetron is described by reaction of 3-(chloromethyl)-1,2,3,9-15 tetrahydro-9-methyl-4H-carbazol-4-one with 2-methylimidazol in DMF (dimethylformamide), which following purification by column chromatography yields ondansetron with a melting point of 228°-229°C. In example 19 the preparation of base ondansetron is described by oxidation 20 of 2,3,4,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-il)methyl]-1H-carbazol maleate with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in THF (tetrahydrofuran), which following purification by column chromatography yields ondansetron with a melting point of 227°C-228.5°C. Example 25 20 describes the preparation of base ondansetron by oxidation of 2,3,4,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-il)methyl]-1H-carbazol-4-ol with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in THF, which following purification by column chromatography yields ondansetron 30 with a melting point of 227.5-229°C.

Patents GB 2220352, EP 385517 and EP 276559 also describe the preparation of ondansetron in accordance with example 7 of the above-cited patent, giving a melting 35 point that coincides with that mentioned in said example.

Other processes have also been described for preparing ondansetron, which processes yield ondansetron with the following melting points: in patent EP 221629, following purification by column chromatography, it decomposes at 215-216°C; in patent EP 219929, following purification by column chromatography, it melts at 216-218°C and, following recrystallisation in methanol, at 227.5-228.5°C; and, finally, in patent ES 2043535, following recrystallisation in methanol, it melts at 227-228.5°C.

That is, all the references mentioned above describe ondansetron with very variable melting points that range from 215°C to 234°C. Following purification by column chromatography they remain variable, from 215°C to 229°C, and following recrystallisation in methanol the melting points rise and centre around 230°C (227-234°C).

International patent WO 03093260 discloses two crystalline forms of base ondansetron, one with a melting point similar to that described in the preceding references and another with a higher melting point, denominated, respectively, Form A and Form B. Form B has a melting point of  $244 \pm 2^\circ\text{C}$  and a powder X-ray diffraction pattern that is characterised by the following peaks: 11.0; 11.2; 14.9; 15.5; 15.9; 16.5; 20.6; 21.4; 23.1; 23.5; 24.2; 24.7; 24.8; 25.8; 26.9; 28.1  $^\circ 2\theta$ . Its preparation is described by dissolving base ondansetron in ethanol or methanol at reflux temperature and subsequent cooling. Form A is characterised by a powder X-ray diffraction pattern that presents the following peaks: 11.0; 11.2; 14.8; 15.4; 16.4; 20.6; 21.4; 23.2; 24.1; 24.7; 25.4; 25.9; 26.7; 27.8  $^\circ 2\theta$ . The preparation of Form A is described by recrystallisation of ondansetron in N,N-

dimethylformamide and by recrystallisation in 1-butanol.

The examples described disclose the preparation of 5 polymorphic forms of ondansetron solely at a scale of a few grams or a maximum of 1.1 kg. Furthermore, in spite of the small amounts of product obtained, the volume of solvent that has to be used is very high (60 L of solvent are required to prepare the maximum amount described, i.e. 10 1.1 kg), thereby hindering its large-scale production.

It is therefore recommendable to have new stable polymorphic forms of ondansetron and processes for manufacturing them that permit the product to be produced 15 at industrial scale.

#### **Description of the invention**

The subject-matter of the present invention is to provide one different polymorphic form of ( $\pm$ )1,2,3,9- 20 tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, known under the INN of ondansetron.

Thus, a first aspect of the invention relates to a new polymorphic form of ondansetron called, hereinafter, 25 Form E, which is characterised by presenting a powder X-ray diffraction pattern, using  $K\alpha_1$  radiation of Cu, in accordance with Figure 1.

Also subject-matter of the present invention is a 30 process for preparing the new polymorphic form of ondansetron denominated Form E.

Another aspect of the present invention is a pharmaceutical composition that contains said new 35 polymorphic form of ondansetron, denominated Form E.

Yet another aspect of the invention is the use of the new polymorphic form of ondansetron denominated Form E for manufacturing a drug for the treatment and prophylaxis of nausea and vomiting.

And an additional aspect of the invention is a therapeutic method for the treatment and prophylaxis of post-operative nausea and vomiting and for the control of nausea and vomiting induced by radiotherapy and cytotoxic chemotherapy.

#### **Description of the figures**

Figure 1 shows the powder X-ray diffraction pattern of the Form E.

#### **Detailed description of the invention**

The polymorphic form of ondansetron, subject-matter of the present invention, is identifiable by its powder X-ray diffraction patterns.

Form E, to which the first aspect of the invention relates, is characterised by a powder X-ray diffraction that presents peaks at  $6.29^\circ$ ;  $11.09^\circ$ ;  $11.88^\circ$ ;  $12.69^\circ$ ;  $14.97^\circ$  and a doublet ( $24.96^\circ$ ;  $25.17^\circ$ )  $2\theta$ . Table 1 below shows the peaks observed in a powder X-ray diffraction pattern of Form E. Table 1 further shows, as additional information, the relative intensity of said peaks.

Table 1

<b>2<math>\theta</math> (°)</b>	<b>I/I<sub>0</sub></b>
<b>6.29</b>	17
7.06	67
10.50	16
<b>11.09</b>	100
<b>11.88</b>	13
<b>12.69</b>	16
13.10	32
13.57	16
<b>14.97</b>	48
16.33	53
16.93	17
17.40	15
18.58	13
19.28	19
20.71	38
21.08	23
21.28	30
22.10	20
24.12	48
24.71	41
<b>24.96</b>	60
<b>25.17</b>	87
25.73	24
26.65	34
26.93	21
28.18	19
28.53	17
29.34	15
29.76	15

Form E presents a powder X-ray diffraction pattern, using the  $K\alpha_1$  radiation of Cu, in accordance with Figure 1.

Advantageously, Form E can also be prepared in a manner reproducible at industrial scale, which makes it the optimum crystalline form of ondansetron for marketing and, therefore, the preferred form.

The powder X-ray diffraction patterns were obtained with  $K\alpha_1$  radiation of Cu, using an INEL CPS-120 appliance with Ge primary monochromator and in 5 transmission geometry with the samples inside 0.5 mm diameter Lindemann glass capillary tubes. The error in determination of the position of the peaks can be estimated at  $\pm 0.05^\circ 2\theta$ .

10 The polymorphic form of the present invention presents a melting point in a range of  $244-247^\circ\text{C}$ . The melting point was determined by DSC, on the basis of the melting peak, using an aluminium crucible with perforated lid at a heating rate of  $10^\circ\text{C}/\text{min}$ .

15

This invention provides a process for manufacturing Form E. Said process comprises:

- a) dissolution of the ondansetron hydrochloride in a mixture of a  $\text{C}_1\text{-C}_3$  alcohol and water;
- 20 b) precipitation of the base ondansetron by basification of the solution;
- c) filtering the solid and washing with water;
- d) suspension of the water-moistened solid obtained in stage c) with methanol at reflux with stirring; and
- 25 e) recovery of the crystalline form;
- f) and filtering and drying the product thus obtained.

Preferably, said  $\text{C}_1\text{-C}_3$  alcohol is methanol.

30 The basification of stage b) can be carried out by means of addition of a solution of sodium hydroxide, potassium hydroxide or aqueous ammonia. Preferably, the basification of stage b) is carried out by addition of an aqueous ammonia solution. Advantageously, the basification 35 with aqueous ammonia produces ammonium chloride as a

residue, which is much more soluble in water and in alcohols than sodium or potassium chloride and therefore much easier to eliminate.

5           Advantageously, said process permits Form E to be obtained in a manner perfectly reproducible at industrial scale. Moreover, as it does not require complete dissolution of the base ondansetron in an alcohol, a solvent in which it is not very soluble, it permits  
10 greater amounts of product to be obtained with very much lower volumes of solvent in comparison with the prior art.

Form E can also be prepared at laboratory scale by means of a process that comprises:

- 15 a) dissolution of the base ondansetron in a C<sub>1</sub>-C<sub>4</sub> alcohol at reflux;  
b) addition of ethyl acetate followed cooling and concentration by slow evaporation at room temperature and  
20 c) recovery of the crystalline form.

Preferably, said C<sub>1</sub>-C<sub>4</sub> alcohol is methanol.

Recovery of the polymorphic form of the present  
25 invention is carried out by filtering the solid and drying, using conventional methods.

In this invention, "a C<sub>1</sub>-C<sub>4</sub> alcohol" is taken to mean methanol, ethanol, n-propanol, isopropyl alcohol, n-  
30 butanol.

The base ondansetron and the ondansetron hydrochloride used as starting product to prepare the polymorphic form of the present invention can be prepared  
35 by any of the processes described in the literature.



Preferably, they are obtained in accordance with the general process described in patent ES 2043535, whose industrial application is carried out with hydrochloric acid as acid catalyst, in a mixture of isopropyl alcohol and water as solvent, which permits the ondansetron to be isolated directly in the form of hydrochloride. The base ondansetron can in turn be obtained by basifying a solution of said hydrochloride.

10 Also subject-matter of the present invention is a pharmaceutical composition that contains said new polymorphic form of ondansetron denominated Form E in a therapeutically active amount and with a suitable amount of at least one excipient.

15

The composition provided by the present invention can be administered by any suitable route, but preferably orally or parenterally.

20 The composition for parenteral or topical administration can be presented in the form of injectable solutions, intravenous solutions, infusions, suppositories or transdermal systems. The pharmaceutical compositions for oral administration can be solids such as tablets or  
25 capsules prepared by the conventional means with pharmaceutically acceptable excipients, or liquids such as aqueous or oleous solutions, syrups, elixirs, emulsions or suspensions prepared by the conventional means with pharmaceutically acceptable additives.

30

Tablets and injectable or intravenous solutions are preferred forms of oral and parental administration, respectively.

An especially preferred pharmaceutical form for administration of Form E of ondansetron is orally disintegrating tablets (also called buccodispersable). Buccodispersable tablets are taken to mean uncoated  
5 tablets for placing in the mouth and having the advantage that they disintegrate rapidly before being swallowed. Various types of technologies have been described for making tablets of this type, and they are known to experts in the subject. Especially preferred are those disclosed  
10 in international patent application WO 03103629.

Said pharmaceutical form can contain a dose of Form E of 2-10 mg.

15 In accordance with conventional pharmaceutical practice, the excipients for the tablet forms can include diluents, disintegrants, wetting agents, lubricants, colorants, flavourings or other conventional adjuvants. Thus, typical tablet excipients include, for example,  
20 lactose, microcrystalline cellulose, corn starch, hypromellose, magnesium stearate, macrogol, polyvinylpyrrolidone, manitol.

The injectable formulations in accordance with the  
25 invention include, preferably, aqueous solutions, with conventional excipients for injectable formulations including sodium citrate, citric acid, sodium chloride, together with water for injections.

30 Also subject-matter of the invention is the use of Form E for manufacturing a drug for the treatment and prophylaxis of post-operative nausea and vomiting and for the control of nausea and vomiting induced by radiotherapy and cytotoxic chemotherapy.

Also subject-matter of the present invention is a therapeutic method for the treatment and prophylaxis of post-operative nausea and vomiting and for the control of nausea and vomiting induced by radiotherapy and cytotoxic chemotherapy, which consists in administering to a patient who so requires a therapeutically effective amount of Form E, preferably in a dose of between 2-10 mg.

### **Experimental Part**

There follow by way of non-restrictive illustration of the invention the following examples.

### **EXAMPLES OF SYNTHESIS**

#### **Example 1**

15

#### **Preparation of Base ondansetron Form E (laboratory method)**

A stirred solution of 4 g of base ondansetron in 200 mL of methanol is heated at reflux to total dissolution. 480 mL of ethyl acetate is added slowly and the heating then switched off and the mixture left to cool slowly down to 20-22 °C. The stirring is stopped and the mixture is left to concentrate slowly with the flask open for 20-30 days until crystals appear, which are filtered and dried at 40°C. 1 g of ondansetron Form E (25%) is obtained.

25

#### **Example 2**

#### **Preparation of Base ondansetron Form E (industrial plant method)**

A stirred suspension of 16 kg of ondansetron hydrochloride in 80 L of methanol and 80 L of water is heated at 30 °C to total dissolution. 6 L of 25% aqueous ammonia is added over the course of 2 hours, until pH 9 is reached. Base ondansetron precipitates out and the resulting suspension

is heated to 35 °C and stirred at that temperature for 1 hour. It is then cooled to 22-25 °C and the suspension is centrifuged. The resulting cake is washed with water (2 x 40 L) and suspended again in 60 L of 5 water. The suspension is stirred at 35 °C for 30 minutes, cooled to 22-25°C and centrifuged again, washing finally with water (2 x 40 L). The water-moistened solid is suspended in 180 L of methanol and the mixture brought to reflux with stirring for 1 hour. The suspension fluidises 10 but does not reach dissolution. It is cooled to 20-22 °C and the suspension is stirred for 30 minutes. It is cooled to 0-5 °C and the suspension is stirred for 1 hour at that temperature. The suspension is centrifuged and the cake washed with 20 L of cold methanol. The product is dried at 15 60°C in vacuo for 15 hours. 10.8 kg of base ondansetron Form E (84%) is obtained.

## CLAIMS

- 5           1. Polymorphic Form E of base ondansetron, characterised in that its powder X-ray diffraction pattern presents characteristic peaks at 6.29°; 11.09°; 11.88°; 12.69°; 14.97° and a doublet at (24.96°; 25.17°) 2 $\theta$ .
- 10           2. Polymorphic form according to Claim 1, characterised in that its powder X-ray diffraction pattern presents the following peaks:

2 $\theta$ (°)
6.29
7.06
10.50
11.09
11.88
12.69
13.10
13.57
14.97
16.33
16.93
17.40
18.58
19.28
20.71
21.08
21.28
22.10
24.12
24.71
24.96
25.17
25.73
26.65
26.93
28.18
28.53
29.34
29.76

3. Polymorphic form according to Claim 2, characterised in that it presents a powder X-ray diffraction pattern in accordance with Figure 1.

5 4. Process for preparing the polymorphic form according to Claim 1, characterised in that it comprises:

- a) dissolution of the ondansetron hydrochloride in a mixture of a C<sub>1</sub>-C<sub>3</sub> alcohol and water;
- b) precipitation of the base ondansetron by basification  
10 of the solution;
- c) filtering the solid and washing with water;
- d) suspension of the water-moistened solid obtained in stage c) with methanol at reflux with stirring; and
- e) recovery of the crystalline form;
- 15 f) and filtering and drying the product thus obtained.

5. Process according to claim 4, characterised in that said alcohol is methanol.

20 6. Process according to Claim 4, characterised in that the basification of stage b) is carried out by addition of an aqueous ammonia solution.

7. Pharmaceutical composition that includes a  
25 polymorphic form according to claim 1, in a therapeutically active amount and with a suitable amount of at least one excipient.


8. A polymorphic form according to claim 1 for use  
30 for manufacturing a drug for the treatment and prophylaxis of post-operative nausea and vomiting and for the control of nausea and vomiting induced by radiotherapy and cytotoxic chemotherapy.

**ABSTRACT**

**New polymorphic form of ondansetron, process for preparing  
5 it, pharmaceutical composition containing it and its use  
as antiemetic**

This invention relates to a new polymorph of ( $\pm$ )1,2,3,9-  
10 tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-  
4H-carbazol-4-one, known under the INN of ondansetron, to  
a process for preparing said polymorph, to pharmaceutical  
composition containing it and to its use in the treatment  
and prophylaxis of nausea and vomiting. The invention  
15 provides a new stable polymorphic form of ondansetron and  
a process for manufacturing it at an industrial scale.

**FIG 1**





**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record.**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**